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Summary 
The Escherichia coli heat-labile enterotoxin (LT) possesses a powerful mucosal 
and systemic adjuvant effect. However, if little is known about the cellular and 
molecular basis of the immunostimulatory activity of LT at the mucosal level, even less 
information is available on the mechanisms underlying its systemic adjuvant activity. 
Here, we show that distinct mechanisms are responsible for the parenteral and mucosal 
adjuvanticity of LT. Indeed, the systemic administration of LT upregulates the 
expression of GITR, but not other activation markers, in naïve T cells. Using wild type 
and GITR-deficient mice and LT and its enzymatically inactive mutant LTK63 as 
adjuvants, we show that the induction of GITR expression in T cells accounts for the 
systemic immunostimulatory capacity of LT which requires an intact enzymatic 
activity. In contrast, the mucosal administration of LT does not induce GITR expression 
on Peyer’s Patches T cells and accordingly no differences are observed in the mucosal 
adjuvanticity of LT between wild type and GITR-deficient mice. Altogether, our results 
demonstrate the distinct effect of LT after parenteral administration as compared to the 
mucosal delivery, and describe a new mechanism of LT adjuvanticity related to its 
ability to induce the expression of GITR in CD4+ T cells. 
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Introduction 
 The Escherichia coli heat-labile enterotoxin (LT) and Vibrio cholerae toxin 
(CT) are two bacterial toxins with a powerful adjuvant capacity [1]. Both toxins consist 
of a monomeric A subunit with enzymatic activity and of a homo-pentameric ring of B 
subunits which binds to the cell surface ganglioside GM1. The enzymatic activity of 
these toxins results in a persistent activation of adenylate cyclase and the increase of 
cytosolic cAMP [2], which disrupts cell homeostasis with a variety of toxic effects [2, 
3]. The high toxicity of LT and CT has stimulated the search for mutants with low or no 
toxicity retaining their immunostimulatory capacity. The LTK63 (Ser to Lys 
substitution at position 63 of the A subunit of LT) and LTR72 (Ala to Arg substitution 
at position 72 of the A subunit of LT) toxoids are two LT mutants with none or a 
reduced enzymatic activity and toxicity, respectively [4, 5]. However, the attenuation of 
the enzymatic activity of these mutants is associated with some decrease in their 
adjuvanticity [4, 5]. Thus, it becomes important to understand the mechanisms that link 
enzymatic activity and adjuvanticity of LT. Most of the present knowledge of the 
adjuvant effects of these molecules is based on experiments with animals immunized 
mucosally, mainly i.n. [6]. However, some reports from animal [7] and human studies 
[8, 9] have raised concerns on the safety of these molecules after i.n. administration. LT 
and LT mutants are also strong adjuvants following parenteral administration [10, 11]. 
However, if little is still known on the fine molecular mechanisms underlying the 
mucosal adjuvanticity of LT and LT mutants, even less information is available on the 
effects triggered by these molecules after systemic administration.  
 
 Several studies point to DC as the principal cellular target of LT and CT 
adjuvanticity in vivo [12, 13]. Both toxins induce the maturation of DC, increasing their 
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antigen presentation capability, their migration to the lymph nodes and their interaction 
with naïve T cells [14]. In addition, CT and LT may act directly on lymphocytes 
inducing their activation and/or cell death [3, 15, 16]. We have previously shown that 
administration of LT promotes an intense but incomplete apoptosis of lymphocytes [5, 
16]. This, together with the capacity of the toxin to stimulate the remaining lymphocytes 
[15], may explain the apparent paradox that an agent which such a potent pro-apoptotic 
activity can be an adjuvant. An interesting observation is that the LT-mediated cell 
death is only observed after its systemic administration [3], suggesting that the 
immunomodulatory properties of LT are highly influenced by the route of toxin 
delivery. Because of the glucocorticoid-mediated effect of LT on apoptosis [3, 16], our 
interest was focused on the glucocorticoid-induced TNFR-related protein (GITR), a 
member of the TNFR superfamily that is constitutively expressed at high levels in Tregs 
and at low levels on conventional CD4+CD25- and CD8+ T cells where it is rapidly up-
regulated after activation [17]. Since GITR-GITRL signalling pathways can influence 
the activation and activity of effector and regulatory T cells as well as DC [17-19], we 
have analyzed the possible role of GITR in the systemic or mucosal adjuvanticity of LT 
in comparison to the enzymatically inactive LTK63 mutant. We report here that the 
systemic adjuvanticity of LT associated with the enzymatic activity is linked to their 
capacity to induce the expression of GITR in T cells. We further demonstrate that the 
mechanisms of adjuvanticity of these immunostimulatory molecules can be distinct at 
different anatomical sites. 
 
Results 
Systemic, but not mucosal, administration of LT induces the expression of GITR in 
naïve T cells. 
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 The expression of a panel of markers associated with lymphocyte activation was 
explored in mature T and B lymphocytes 72 hrs after systemic LT administration. 
Injection of 1 μg of LT into the footpad (f.p.) of BALB/c mice caused a marked 
reduction in the number of total CD4+ cells in the spleen and of CD4+ T cells that were 
either CD25+, CD69+, CTLA-4+, CD45RB-/low or CD62L- (Figure 1A). Remarkably, the 
number of CD4+ T cells expressing high levels of GITR remained unchanged after LT 
administration (Figure 1A).  
 
Since LT promotes an intense T-cell apoptosis [3, 16], we explored whether the 
maintenance in the number of CD4+GITRhigh cells after LT treatment could reflect an 
enhanced resistance of these cells to LT induced apoptosis and/or an expansion of this 
cell population. For that, we explored first the effects of LT in BALB/c mice after 
bilateral adrenalectomy, which severely impairs LT-induced lymphocyte apoptosis [3, 
16]. In these adrenalectomized mice, f.p. treatment with LT did not modify significantly 
the numbers of CD4+CD69+, CD4+CTLA-4+, CD4+CD45RB-/low or CD4+CD62L- cells 
and slightly reduced the number of CD4+CD25+ cells (Figure 1A). In contrast, the 
number of CD4+CD25-GITRhigh cells was increased in these mice (Figure 1A). In 
addition, no differences in the susceptibility of peripheral CD4+ T cells to f.p. LT-
induced apoptosis were found between Sv129-GITR–/– mice and wild type littermates 
[nº of spleen CD4+ T cells (x106) in; Sv129 wild type mice receiving PBS: 16.7 ± 1.3, 
or 1 μg of LT: 5.7 ± 0.4 (n= 4); in Sv129-GITR–/– mice receiving PBS: 13.6 ± 4.6, or 1 
μg of LT: 4.3 ± 0.8 (n= 3)]. Induction of GITR expression was observed in CD4+CD25-
FoxP3- T cells but not in CD4+CD25+FoxP3+ Tregs (Figure 1B). The expansion of 
CD4+CD25-GITRhigh cells in adrenalectomized mice was evident as early as 24 hrs after 
LT administration, returning to basal levels 10 days later (Figure 1C) and was dose 
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dependent (Figure 1D). A similar increase in CD4+CD25-GITRhigh cells was observed 
72 hrs after f.p. administration of LT in C57BL/6 (B6) Tg mice overexpressing in T 
cells both a dominant negative form of FADD (FADD-DN) and human Bcl-2 (hBcl-2) 
(Figure 1E) and which are refractory to the LT-induced apoptosis of mature T cells [16]. 
LT also promoted the expression of GITR in inguinal and mesenteric lymph node cells 
and purified CD4+CD25- spleen T cells stimulated in vitro with LT during 24 hrs (Table 
1). Finally, f.p. injection of LT into bilateral adrenalectomized BALB/c mice increased 
the number of CD8+GITRhigh cells but not of B220+GITRhigh cells (Figure 1F). 
 
To investigate whether the expansion of CD4+CD25-GITRhigh cells in the LT 
treated mice was due to the induction of GITR expression in naïve CD4+ T cells or to 
the proliferation of pre-existing CD4+CD25-GITRhigh cells, bilateral adrenalectomized 
BALB/c mice were treated with BrdU prior and after the f.p. injection of LT. 72 hrs 
after toxin administration the percentage of spleen CD4+BrdU+ cells was similar to that 
found in untreated mice (Figure 2). In addition, LT did not promote an increase in 
CD8+BrdU+ and B220+BrdU+ cells in these mice (Figure 2).  
 
We further investigated the capacity of LT to induce GITR expression in 
lymphocytes after mucosal administration. Intragastric (i.g.) administration of 10 or 50 
μg of LT into BALB/c mice failed to promote GITR expression 48 hrs later in 
CD4+CD25- T cells from both the Peyer’s Patches (% of CD4+GITR+ T cells in, 
untreated: 19.7 ± 2.1%; treated with 10 μg of LT: 18.6 ± 1.3%; treated with 50 μg of 
LT: 25.1 ± 4.1%; n=5; p>0.08 in all cases) and the draining mesenteric lymph nodes (% 
of CD4+GITR+ T cells in, untreated: 18.9 ± 4.6%; treated with 10 μg of LT: 16.1 ± 
1.9%; treated with 50 μg of LT: 21.7 ± 4.5%; n=5; p>0.08 in all cases), even after 
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treatment with Neomycin before (48 hrs) and after toxin administration (data not 
shown). Similarly, LT (10 μg) did not induce GITR in CD4+CD25- T cells from the 
draining mediastinal lymph nodes when administered intranasally (i.n., data not shown). 
In contrast, in vitro stimulation of Peyer´s Patches cells with LT during 24 hrs strongly 
induced the expression of GITR on CD4+CD25- T cells at levels comparable to those 
observed in in vitro LT-stimulated CD4+CD25- T cells from mesenteric lymph nodes 
(Table 1).  
 
T-cell induction of GITR by LT requires its enzymatic activity and is specific of 
this adjuvant. 
To explore whether the enzymatic activity of LT was required to induce the 
expression of GITR in CD4+ T cells, bilateral adrenalectomized BALB/c mice were 
injected into the f.p. with 1 or 30 μg of either the enzymatically inactive or the partially 
active LTK63 and LTR72 mutants, respectively [4, 5]. At the higher dose, but not with 
the lower dose, of the toxins the partially active LTR72 mutant, but not the fully 
detoxified LTK63 mutant, was able to induce GITR expression in naïve CD4+CD25- T 
cells (Figure 3 and data not shown).  
 
We then investigated the capacity of different adjuvants/immunostimulators 
such as CFA, aluminium hydroxide (Alum) and MF59 or LPS, to regulate GITR 
expression in CD4+ T cells from BALB/c mice. None of these 
adjuvants/immunostimulators administered i.p. modified significantly the numbers of 
CD4+CD25-GITRhigh cells in the spleen of these mice (Figure 3).  
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Systemic administration of LT blocks the induction of tolerance by a GITR-
dependent mechanism.  
Pre-treatment of adult mice with monomeric deaggregated human 
gammaglobulin (DHGG) induces immunological tolerance against the immunogenic 
and aggregated HGG (AHGG) in murine mature lymphocytes [20]. Using this 
experimental model we first compared the capacity of LT and LTK63 to interfere with 
the induction of immunological tolerance. BALB/c mice injected i.p. on day 0 with 3 
mg of DHGG and boosted 10 days later with 400 μg of AHGG, failed to produce IgG 
anti-HGG Abs 7 days after AHGG immunization (Figure 4A). As previously reported 
[20], mice receiving LPS at the time of DHGG treatment produced high levels of IgG 
anti-HGG Abs (Figure 4A). A similar rupture of tolerance was observed when DHGG-
injected BALB/c mice received 1 μg of LT into the f.p., but not 5 μg of LTK63 (Figure 
4A). In contrast, the f.p. treatment with 0.1 μg of LT failed to block the induction of 
tolerance to HGG (data not shown), in agreement with the absence of induction of 
GITR expression in T cells (Figure 1D). The induction of tolerance in this model was 
not due to the activity of Tregs. Thus, DHGG-tolerized BALB/c mice depleted in Tregs 
after treatment with an anti-CD25 mAb, did not produce significant levels of IgG anti-
HGG Abs after AHGG immunization, in contrast with non-tolerized but AHGG 
immunized BALB/c mice depleted in Tregs (Figure 4A).  
 
We then explored the role of the induction of GITR in CD4+ T cells in the 
mechanism of systemic adjuvanticity of LT. The engagement of GITR with the 
agonistic anti-GITR mAb DTA-1 [18] at the time of DHGG injection blocked the 
induction of tolerance to HGG and these mice exhibited increased serum levels of IgG 
anti-HGG Abs (Figure 4A). Interestingly, f.p. administration of LT into Sv129-GITR-/- 
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mice failed to block the induction of tolerance to HGG, as efficiently as observed in 
wild type controls; these mice had reduced levels of IgG anti-HGG Abs that were at 
titres close, although slightly higher, to those found in DHGG-AHGG tolerized controls 
(Figure 4B).  
 
LT and LTK63 exhibit similar systemic but not mucosal adjuvanticity in GITR-/- 
mice. 
In view of the potential importance of GITR induction in CD4+ T cells in the 
systemic adjuvanticity of LT associated with its enzymatic activity, we have explored 
whether in an immunization protocol where LT and LTK63 trigger an immune response 
to a co-administered antigen, the systemic adjuvanticity of both toxins will be similar in 
GITR-/- mice. Sv129-GITR-/- and wild type mice were primed and boosted 20 days later 
i.p. with OVA using LT, LTK63 or CFA/IFA as adjuvants. According to previous 
studies [4, 5], 15 days after the second immunization the levels of IgG anti-OVA Abs 
were higher in wild type mice immunized with OVA-LT than in wild type mice 
immunized with OVA-LTK-63 (Figure 5A). However, an important reduction in the 
levels of IgG anti-OVA Abs was observed in Sv129-GITR-/- mice immunized i.p. with 
OVA-LT that were similar to those found in both groups of mice immunized i.p. with 
OVA-LTK63 (Figure 5A). As a control, no differences in the levels of IgG anti-OVA 
Abs were observed between wild type and Sv129-GITR-/- mice when CFA/IFA was 
used as adjuvant (Figure 5A). The decreased IgG anti-OVA Ab production observed in 
LT-OVA immunized Sv129-GITR-/- mice was associated with a selective reduction in 
the levels of IgG2a anti-OVA Abs (p<0.01), being the titres of IgG1 and IgG2b anti-
OVA Abs similar between both groups of animals (p>0.05 in both cases) (Figure 5B). 
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Finally, similar levels of circulating IgA anti-OVA Abs were measured in both groups 
of mice (data not shown).  
 
To explore the mechanisms accounting for the selective reduction of IgG2a anti-
OVA Abs in LT-treated Sv129-GITR-/- mice, the expression of IFNγ and IL-4 in the 
spleen was compared between bilateral adrenalectomized Sv129-GITR-/- and wild type 
mice treated i.p. with 1 μg of LT by real time quantitative RT-PCR. An increase in IFNγ 
and IL-4 mRNA transcripts was observed in the spleen of Sv129 wild type mice 5 days 
after LT administration (Figure 5C). The expression of IL-4 was also enhanced in the 
spleen of LT-treated Sv129-GITR-/- mice but the levels of IFNγ mRNA were essentially 
identical to those of PBS treated Sv129-GITR-/- controls (Figure 5C).  
 
We finally compared the mucosal adjuvanticity of LT and LTK63 between wild 
type and Sv129-GITR-/- mice immunized and boosted i.n. with OVA dissolved in either 
PBS, 10 μg of LT or LTK63. No differences in the levels of circulating IgG, IgA or the 
different IgG subclasses (Figure 6 and data not shown) anti-OVA Abs were observed 
between LT-OVA i.n immunized wild type and Sv129-GITR-/- mice 14 days after the 
boost. Serum levels of IgG anti-OVA Abs were also similar between wild type and 
Sv129-GITR-/- mice immunized i.n. with LTK63-OVA but significantly lower 
(p<0.001) than those observed in mice receiving LT as adjuvant (Figure 5B).  
 
Discussion 
The unique property of LT to act as a potent mucosal and systemic adjuvant has 
stimulated many studies aimed at understanding its mechanism of action [21]). Here, we 
demonstrate that LT induces the expression of GITR, but not other activation markers, 
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on T cells when administered systemically by a mechanism that requires the enzymatic 
activity of the toxin and is independent of endogenous glucocorticoids. This effect 
seems specific of LT since is not observed with other commonly used adjuvants or 
immune stimulators. The induction of GITR expression in CD4+ T cells accounts for the 
systemic adjuvanticity of LT which is associated to its enzymatic activity. Finally, the 
inability of LT to promote GITR expression in Peyer´s Patches T cells after its mucosal 
administration and the fact that wild type and GITR-/- mice respond equally to i.n. 
administered antigens using either LT or LTK63 as adjuvants, clearly indicates that the 
mechanisms of adjuvanticity of these toxins are highly influenced by their route of 
administration. 
 
We describe a novel mechanism of systemic adjuvanticity of LT linked with the 
capacity of the toxin to induce the expression of key costimulatory molecules, such as 
GITR, in CD4+ T cells. Since LT causes apoptosis of mature lymphocytes, the 
accumulation of CD4+GITRhigh cells after toxin administration may reflect a particular 
resistance of this cell population to cell death signals, as it has been suggested 
previously [22]. It is theoretically possible that in situations where the ability of LT to 
promote T cell apoptosis is inhibited, the relative proportion of CD4+GITRhigh and 
CD4+GITRlow cells will be close to that observed in untreated mice and that such 
resistance will be not observed in mice deficient in GITR. However, although we can 
not totally exclude this possibility, our results demonstrate a similar susceptibility of 
CD4+ T cells from Sv129 wild type and GITR–/– mice to LT-induced apoptosis and an 
expansion of CD4+GITRhigh cells in both bilateral adrenalectomized BALB/c mice and 
B6 mice overexpressing in T cells FADD-DN and hBcl-2 transgenes, which are largely 
protected against LT-induced apoptosis of mature T cells [3, 16].  
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 In view of the role of GITR in T cells, GITR signalling may contribute to the 
adjuvanticity of LT by acting as an activation-induced costimulatory signal in 
CD4+CD25- T cells that increase their TCR-induced proliferation and cytokine 
production [17]. Signalling through GITR may also inhibit the suppressive capacity of 
Tregs [18] or may render CD4+CD25- T cells more resistant to the Treg-mediated 
suppression [17], also contributing in that way to the immunostimulatory capacity of 
LT. However, against this last possibility is the fact that LT interferes with the 
establishment of lymphocyte tolerance in a model in which such tolerance induction is 
independent of Treg activity. Alternatively, the induction of GITR expression in CD4+ 
T cells may influence the adjuvanticity of LT by regulating the activity of DC. GITR is 
activated by its ligand (GITRL), which is expressed in APCs [17]. Although our 
preliminary observations fail to show changes in the expression of GITRL on APC after 
LT administration (unpublished observations), it is also possible that GITRL, 
interacting with the upregulated GITR receptor in T cells, may deliver signals to APC 
by means of its cytoplasmic domain [19]. In this regard, DC cocultured with activated 
CD4+ T cells from GITR-/- mice and stimulated with heat-inactivated Candida albicans 
produce high amounts of IL-12 [23]. However this Th1 polarization observed in GITR-/- 
mice during Candida albicans immune responses clearly contrasts with the reduction in 
the levels of circulating IgG2a (the classical Th1 IgG subclass) anti-OVA Abs and with 
the absence of induction of IFNγ gene expression in the spleen of these LT-treated 
GITR-/- mice. Whether the different nature of these two antigens may explain these 
apparently conflicting observations is at present unknown.  
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LT retains, although at decreased levels, a prominent systemic 
immunostimulatory capacity in GITR-/- mice that is similar in intensity to the 
adjuvanticity of LTK63 in wild type and GITR-/- mice. Thus, other still unknown 
mechanisms have to be involved in the capacity of LT to stimulate the immune system, 
mechanisms which are very likely shared by the LTK63 mutant, and which may be 
linked to the holotoxin structure or to their receptor binding capacity. In particular, 
GM1 crosslinking induces the activation of T cells and the B subunit of CT or LT are 
capable of substituting for costimulation during T cell activation or to elicit humoral 
immune responses in mice, respectively [24-27]. However, the B subunit of LT 
promotes the induction of immunological tolerance to antigens co-administered orally 
[28], suggesting that the crosslinking of GM1 by LT or LTK63 may contribute to the 
adjuvanticity of these toxins only in certain experimental conditions. 
 
Unlike the systemic route, the mucosal administration of LT does not induce the 
expression of GITR on T cells in both Peyer’s Patches and draining mesenteric lymph 
nodes. In agreement with these results, no differences in the LT adjuvanticity are 
observed between wild type and GITR-/- mice. Since LT promotes a rapid and strong 
upregulation of GITR expression in Peyer’s Patches CD4+CD25- T cells in vitro, the 
effects observed in vivo are unrelated to the presence of intrinsic defects in these 
mucosal T cells. Although doses of LT 10 to 50 times higher than those used 
systemically and administered with Neomycin fail to induce GITR expression in T cells, 
such absence of GITR induction after mucosal delivery of LT may be due to differences 
in the availability of the toxin when given parenterally or mucosally secondary to an 
enhanced degradation of the toxin. However, the fact that these high doses of LT 
administered i.n. have a strong immunostimulatory activity against co-administered 
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antigens, clearly indicates that the mucosal adjuvanticity of LT is unrelated to GITR. 
Thus, our results provide evidences that the mechanisms of adjuvanticity of LT are 
highly influenced by the route of administration of the toxin. Other groups have 
demonstrated that the i.g. administration of CT enhances the expression of B7-2 
molecule on B cells and macrophages and that this induction is critical for the mucosal 
adjuvanticity of the toxin [29]. However, it remains unclear whether a similar 
upregulation of B7-2 expression is observed after mucosal or systemic administration of 
LT.  
 
 In summary, here we have demonstrated that distinct mechanisms can be in 
place when adjuvants such as LT are administered parenterally or mucosally. In fact, the 
systemic adjuvanticity of LT which is linked to its enzymatic activity is mediated 
through the regulation of GITR expression in CD4+ T cells. The induction of Bell's 
palsy in some healthy subjects receiving i.n. LT or LT mutants containing vaccines [8, 
9] supports the possibility of using these adjuvants via the parenteral route. In this light, 
our study provides insights into the understanding of immunomodulatory properties of 
LT and related toxins that may lead to the harnessing of such activities in safer forms.  
 
Materials and Methods 
Mice and surgery. 
BALB/c mice were obtained from Harland Iberica (Barcelona, Spain). B6-
prLck.hbcl-2 Tg mice were obtained by backcrossing C3H/HeN.Lck.hbcl-2 Tg mice 
(Jackson Laboratories, Bar Harbor, ME) with B6 mice. B6. prLck.hbcl-2 Tg mice were 
crossed with B6 Tg mice overexpressing FADD-DN in T cells [30], generously 
provided by Dr Andreas Strasser, (The Walter and Eliza Hall Institute of Medical 
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Research, Australia), to obtain double-Tg mice. Sv129-GITR–/– mice were generated by 
homologous recombination as previously described [31]. 
 
Adrenal glands were removed as described [3]. LT toxin was administered 2 
days after surgery. 
 
All experiments were performed in 6-8 wk old animals and approved by the 
Universidad de Cantabria Institutional Laboratory Animal Care and Use Committee. 
 
Adjuvants and immunization protocols. 
LT and their mutants, MF59 and Alum were obtained from Novartis Vaccines 
(Siena, Italy). The CFA and IFA were purchased from Sigma (St Louis, MO). The 
doses of LT and LT mutants used here were chosen according to our previous studies 
[3, 16]. For i.g. administration of toxins (10 or 50 μg of LT or 30 μg of LTK63), 
animals received previously 200 μl of 1M carbonate-bicarbonate buffer and 100 μg of 
omeprazole (Sigma) and were maintained under Neomycin treatment (SALVAT 
Laboratories, Barcelona, Spain), administered in the drinking water at a concentration of 
5 mg/l). 
 
DHGG and AHGG were prepared from HGG (Baxter S.L., Valencia, Spain) as 
described previously [20]. Mice were treated i.p. (BALB/c mice) or i.v. (Sv129 mice) 
with 3 mg of DHGG and boosted i.p. 10 days later with 400 µg of AHGG dissolved in 
saline (BALB/c mice) or emulsified in CFA (Sv129 mice). In some experiments, 50 µg 
of LPS, 1 or 0.1 µg of LT or 5 µg of LTK63 were injected i.p. 3 hrs after DHGG 
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injection. The presence of IgG anti-HGG Abs in sera was measured by ELISA 7 days 
after the AHGG boost, as described [20]. 
 
In some experiments, Sv129-GITR–/– mice and wild type littermates were 
immunized i.p. with 100 µg of OVA together with either 1 µg of LT or 5 µg of LTK63. 
A similar boost was performed 20 days later. As a control, mice were immunized with 
100 µg of OVA-CFA and boosted with 100 µg of OVA-IFA 20 days later. The mucosal 
adjuvanticity of toxins were tested by immunizing i.n. Sv129-GITR–/– mice and wild 
type littermates on days 0 and 21 with 10 µg of toxins and 10 µg of OVA, or with 
antigen alone. In all experiments, the titres of IgA, IgG and IgG subclass specific anti-
OVA Abs in sera were measured by ELISA 15 days after the boost, as described [5]. 
 
Induction of apoptosis by LT. 
Sv129-GITR–/– mice and wild type littermates were injected into the f.p. with 1 
μg of LT and the induction of apoptosis of CD4+ T cells was evaluated 72 hrs later as 
described previously [3, 16].  
 
Flow cytometry studies. 
Frequencies of lymphocyte populations were evaluated in the spleen, mesenteric 
lymph nodes or Peyer’s Patches by flow cytometry 48-72 hrs after the administration of 
toxins using conjugated mAbs (Becton Dickinson Biosciences, Madrid, Spain). Cells 
were analyzed using a FACScalibur flow cytometer using the Cell Quest Pro software 
(Becton Dickinson). 
 
CD4+CD25- T cell purification and in vitro assay. 
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Purified CD4+CD25- spleen cells, using the mouse CD4+ isolation kit (Miltenyi 
Biotec, Madrid, Spain)or total Peyer’s Patches, inguinal or mesenteric lymph node cells 
(5 x105 cells/well) from 2 month old BALB/c were either non-stimulated (medium) or 
stimulated in vitro with LT (0.5 µg/ml) during 24h. GITR expression on viable cells 
was evaluated by flow cytometry. 
 
In vivo proliferation assay. 
Mice received an i.p. injection of 1 mg of BrdU (Sigma) prior to the treatment 
with 1 µg LT and maintained with BrdU in the drinking water (0.8 mg/ml) during the 
following three days. The incorporation of BrdU in mature B and T spleen cells was 
evaluated by flow cytometry 72 hrs after LT administration, as described previously 
[32]. 
 
Treatment with mAbs. 
For CD4+CD25+ T cell depletion, mice received one daily i.p. injection of 0.2 
mg of anti-CD25 mAb (clone PC61) during three days one week before the 
immunization with AHGG or DHGG. The efficiency of the treatment was confirmed by 
flow cytometry. In some experiments, mice received i.p. 1 mg of an agonistic anti-GITR 
mAb (DTA-1) [18], generously provided by Dr Simon Sakaguchi (Kyoto University, 
Kyoto, Japan), at the time of DHGG tolerization.  
 
Real time RT-PCR assays. 
Total RNA was obtained from the spleen of bilateral adrenalectomized Sv129-
GITR–/– mice and wild type littermates 5 days after i.p. injection of 1 μg of LT or PBS 
and used for cDNA synthesis with a RT-PCR kit (Fermentas, Quimigen S.L., Madrid). 
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Quantitative, real time PCR was conducted on a MX-3000P Stratagene instrument (La 
Jolla, CA) using specific TaqMan POMC expression assays (Applied Biosystems, Life 
Technologies). Results (in triplicate) were normalized to GAPDH expression. Data were 
expressed as mean fold change relative to control samples (n= 5 mice/group). 
 
Statistical analysis. 
Statistical analysis was performed using the two-tailed Student´s t test or the Mann-
Whitney test. Probability values <0.05 were considered significant. 
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Figure Legends 
Figure 1. Transient T-cell induction of GITR expression after systemic injection of 
LT. A) Expression of activation markers in CD4+ T cells in the spleen 3 days after f.p. 
injection of 1 μg of LT or PBS into normal or bilateral adrenalectomized (Adrx) 
BALB/c mice. The reduction (↓) and increase (↑) indexes after LT treatment are 
indicated. B) Induction of GITR expression on CD4+CD25-FoxP3- but not on 
CD4+CD25+FoxP3+ T cells from bilateral adrenalectomized BALB/c mice. C) Kinetics 
of GITR induction in CD4+ T cells in the spleen of bilateral adrenalectomized BALB/c 
mice after f.p. injection of LT. D) Dose dependent induction of GITR expression on 
CD4+ T cells in the spleen of bilateral adrenalectomized BALB/c mice 72 hrs after f.p. 
injection of LT. E) Number of CD4+GITRhigh T cells in the spleen of B6.Lck.hbcl-
2/FADD-DN double-Tg mice 3 days after the f.p. injection of PBS or 1 μg of LT. F) 
Number of CD8+GITRhigh T and B220+GITRhigh cells in the spleen of bilateral 
adrenalectomized BALB/c mice treated with PBS or with 1 μg of LT into the f.p. The 
results, representative of at least 2 independent experiments (n=5 mice per group), are 
expressed as the mean ± SEM of the number of viable cells (A, C-F) or MFI of GITR 
expression (B) of the indicated populations. Statistic differences between PBS and LT 
treated animals, evaluated by the Student´s t test, are indicated as follow: ns. non-
significant, *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 2. LT fails to induce the proliferation of mature B and T cells. Percentages 
of BrdU+-B220+, BrdU+-CD4+ or BrdU+-CD8+ splenocytes in bilateral 
adrenalectomized BALB/c mice 3 days after f.p. administration of LT expressed as the 
mean ± SEM. Results are representative of 3 independent experiments (n=5 mice per 
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group). No statistic differences, evaluated by the Student´s t test, were observed 
between PBS and LT treated animals. 
 
Figure 3. The LT induction of GITR in T cells requires its enzymatic activity and 
is specific of this adjuvant. BALB/c mice (3-5 mice/group) were injected into the f.p. 
with 1 μg of LT, 30 μg of LTR72 or LTK63 or i.p. with 200 μl of CFA (50% v/v), 50 
μg of LPS, 1 mg of Alum or 200 μl of MF59 (50% v/v). Representative panels of 2 
independent experiments show the expression of GITR in CD4+CD25- splenocytes 
(solid line) measured by flow cytometry 72h later. Dotted lines represent background 
fluorescence. The mean ± SEM of the number of CD4+GITRhigh cells (top) and the 
mean fluorescence intensity (MFI) of GITR expression (bottom) are indicated. Statistic 
differences between PBS and adjuvant treated animals, evaluated by the Student´s t test, 
are indicated as follow: ns. non-significant, ***p<0.001. 
 
Figure 4. LT but not LTK63 blocks the induction of tolerance to HGG by a GITR-
dependent mechanism. A) Two month-old BALB/c mice were tolerized with DHGG 
and immunized i.p. with AHGG 10 days later. Non immunized mice or animals injected 
i.p. with AHGG were used as controls. Tolerized mice were either untreated or treated 
with LPS, LT or LTK63 i.p. at the time of DHGG injection or treated with either a 
cytotoxic anti-CD25 mAb or an agonistic anti-GITR mAb (DTA-1). B) Two month-old 
Sv129-GITR-/- mice or wild type littermates were tolerized with DHGG and treated or 
not with 1 μg of LT 10 days before the immunization with AHGG-CFA. The presence 
of circulating IgG anti-HGG Abs was evaluated 7 days later by ELISA. Values of 
individual mice are expressed in TU. Bars represent the mean value of each 
examination. Statistic differences between PBS and LT treated animals, evaluated by 
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the Mann-Whitney test, are indicated as follow: ns. non-significant, *p<0.05, **p<0.01, 
***p<0.001. Results are representative of 3 independent experiments. 
 
Figure 5. The expression of GITR in T cells modulates the systemic adjuvanticity 
of LT. A) Two month old Sv129-GITR–/– and wild type littermates were immunized i.p. 
and boosted 20 days later with 100 µg of OVA dissolved in saline or coadministered 
with either 1 µg of LT or 5 µg of LTK63. Control mice were immunized with 100 µg of 
OVA emulsified in CFA and boosted with 100 µg of OVA emulsified in IFA 20 days 
later. Bars represent the mean ± SEM of the titres of IgG anti-OVA Abs in sera 15 days 
after the boost. Results are representative of 2 independent experiments. B) Levels of 
IgG1, IgG2a and IgG2b anti-OVA Abs in the same sera than A. Values of individual 
mice are expressed in TU. Bars represent the mean value of each examination. Statistic 
differences between the groups, evaluated by the Mann-Whitney test, are indicated as 
follow: ns. non-significant, **p<0.01. C) Expression of IFNγ and IL-4 mRNA in the 
spleen of bilateral adrenalectomized BALB/c mice 5 days after f.p. injection of 1 μg of 
LT evaluated by real time quantitative RT-PCR. Results for each cytokine are 
normalized to GAPDH expression an expressed as the mean ± SD of 5 mice per group. 
Statistic differences between PBS and LT treated animals, evaluated by the Student´s t 
test, are indicated as follow: *p<0.05, **p<0.01. 
Figure 6. The expression of GITR in T cells does not influence the mucosal 
adjuvanticity of LT. A) Two month old Sv129-GITR–/– and wild type littermates were 
immunized and boosted 21 days later i.n. with 10 µg of OVA dissolved in PBS or 
coadministered with either 10 µg of LT or LTK63. The levels of circulating IgG anti-
OVA Abs were evaluated 15 days after the boost. Values of individual mice are 
expressed in TU. Bars represent the mean value of each examination. Statistic 
 26
differences between the groups, evaluated by the Mann-Whitney test, are indicated as 
follow: ns. non-significant, ***p<0.001. 
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Table 1. In vitro induction of GITR expression on CD4+ T cells by LT.  
 % of CD4+GITR+  MFI of GITR
 Medium  LT Medium  LT 
Purified CD4+CD25- cells 18.1 ± 0.9  82.8 ± 6.1 11.2 ± 0.6  33.8 ± 1.8 
Inguinal lymph node cells 16.6 ± 2.4  75.2 ± 3.5 14.9 ± 0.4  31.8 ± 2.4 
Mesenteric lymph node cells 18.3 ± 1.2  76.8 ± 4.8 10.8 ± 0.3  37.9 ± 0.6 
Peyer’s Patches cells 17.7 ± 2.4  73.2 ± 1.7 14.1 ± 1.1  33.5 ± 2.1 
The indicated cells (5 x105 cells/well) from 2 month old BALB/c were either non-
stimulated (medium) or stimulated in vitro with LT (0.5 µg/ml) during 24h. Results are 
expressed as the mean ± SD of the percentage of GITRhigh cells and the MFI of GITR 
expression in viable CD4+CD25- cells in triplicate cultures, evaluated by flow 
cytometry. 
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